Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast
12 févr. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and...
Sucampo Names Peter Greenleaf Chief Executive Officer
10 févr. 2014 16h02 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced that Peter Greenleaf will join Sucampo as Chief Executive Officer ("CEO") and...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Leerink Global Healthcare Conference
05 févr. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will present, via "fireside chat"...
Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation
17 déc. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013 Credit Suisse Healthcare Conference
06 nov. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation
23 oct. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo Pharmaceuticals Announces Third Quarter and Nine Months 2013 Results and Operating Highlights Teleconference and Webcast
22 oct. 2013 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced that it will host a webcast and...
Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
21 oct. 2013 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced that its development partner, R-Tech Ueno, Ltd....
Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
11 oct. 2013 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in...
Sucampo Announces Presentation of Results on Lubiprostone in Pediatric Functional Constipation at NASPGHAN 2013
10 oct. 2013 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of results from a Phase 3, open-label safety and efficacy...